New Inhalable Dry Antiviral Powder May Be Effective Against COVID

A new inhalable dry powder formulation of tamibarotene that shows broad-spectrum antiviral activity against SARS-CoV-2 has been developed by scientists.

A new inhalable dry powder formulation of tamibarotene has been developed by scientists. The drug has showed broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV and influenza A H1N1 virus following pulmonary delivery in animal models.

Tamibarotene is available as an oral tablet for the treatment of acute promyelocytic leukemia currently marketed in Japan. But when a high dose is administered to compensate for the insufficient lung distribution, toxic side effects are expected because of the extensive systemic exposure.

Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization
Fluvoxamine has been proven among one such drug that could be used to treat COVID-19. Dozens of COVID patients showed no clinical deterioration in their symptoms when treated with a drug, fluvoxamine.

‘Inhaled powder formulation of broad-spectrum antiviral drugs can be used on an outpatient basis due to the ease of (self-)administration as prevention and treatment for respiratory viral infections.’

By contrast, pulmonary delivery is a non-invasive administration route that can maximise local concentration in the lung and reduce systemic exposure, thereby reducing the risk of adverse effects and improving therapeutic efficacy.

The team, led by the University of Hong Kong (HKUMed), prepared the inhaled dry powder formulation of tamibarotene by spray freeze drying, a particle engineering technique that combines spray freezing and freeze drying to produce particles with excellent aerosol properties for inhalation.

The researchers found that a dose of tamibarotene powder delivered by intratracheal administration significantly reduced virus titer and viral RNA load of SARS-CoV-2 in the hamsters' lungs, and the antiviral efficacy was comparable to intratracheally administered remdesivir.

Green Fungus or Aspergillosis and COVID-19 Infection
Green fungus or Aspergillosis is caused by a common mold, which exists both indoors and outdoors. Every day, people inhale Aspergillus spores, but it isn't harmful. However, it affects people who have a weak immune system. If the infection is left untreated, it can cause pneumonia.

Moreover, remarkable anti-influenza activity of tamibarotene powder formulation was demonstrated by the improved survival rate of mice and alleviated disease severity when administered either intratracheally as prophylaxis or intranasally as treatment. The findings have been published online in Advanced Therapeutics.

"Currently, there is no inhaled powder formulation of antiviral available on the market for Covid-19 treatment. Tamibarotene dry powder with broad-spectrum antiviral activity presents a new strategy for Covid-19 management, especially as prophylaxis and treatment for outpatients when in-patient healthcare cannot be provided," said Jenny Lam, Associate Professor, Department of Pharmacology and Pharmacy, HKUMed.

Mucormycosis (Black Fungal Disease): A Complication of COVID-19
Mucormycosis is spread by spores from the black fungus, Mycormycetes. It mainly affects people with a weak immune system and attacks the lungs and other organs of the body. It is also known as Black Fungal Disease.

"With the favourable safety profile of tamibarotene and based on the findings in the present study, clinical trials evaluating inhaled tamibarotene for its safety and as at-home treatment for Covid-19 could be considered," Lam said.

Source-IANS

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.